Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer

Phase 1/2 Completed 63 enrolled AGO Study Group

Non-randomizedSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining liposomal doxorubicin with carboplatin in treating patients who have gynecologic cancer.

Timeline

Start: 2001-08
Primary completion: 2005-05
Completion: —

Publications

Results du Bois A, Pfisterer J, Burchardi N, Loibl S, Huober J, Wimberger P, Burges A, Stahle A, Jackisch C, Kolbl H; Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom; Kommission Uterus. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut). Gynecol Oncol. 2007 Dec;107(3):518-25. doi: 10.1016/j.ygyno.2007.08.008. Epub 2007 Oct 25.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Doxorubicin	Other / unclassified	20 mg/m2	Intravenous
Subject	Doxorubicin	Other / unclassified	30 mg/m2	Intravenous
Subject	Doxorubicin	Other / unclassified	40 mg/m2	Intravenous
Background	Carboplatin	Small molecule	6 unknown	Intravenous

Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer

Summary

Timeline

Publications

Drugs

Indications